

## Recent Publications: year 2006

48 original publications

1. Becker C, Hvalic C, Delmore G, Krähenbühl S, Schlienger R. Recurrent acute pancreatitis during pravastatin-therapy. *Schweiz Rundsch Med Prax.* 2006 Jan 25; 95(4):111-6.
2. Becker C, Drewe J. Interaktionen zwischen Antiepileptika und Arzneimitteln zur Therapie und Prophylaxe der Migräne. *Epileptologie* 23 (1): 14-22 (2006)
3. Beltinger J, Haschke M, Kaufmann P, Michot M, Terracciano L, Krähenbühl S. Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide and roxithromycin. *Ann Pharmacother* 2006; 40:767-70
4. Bodmer M. Interaktionen zwischen Antiepileptika und kardiovaskulären Medikamenten. *Epileptologie* 23(1): 8-13 (2006)
5. Bodmer M, Egger SS, Hohenstein E, Beltraminelli H, Krähenbühl S. Lichenoid drug eruption associated with the use of nebivolol. *Ann Pharmacother*; 40:1688-90 (2006).
6. Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krähenbühl S. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. *Digestion* 74:28-32 (2006)
7. Bottomino A, Bruppacher R, Krähenbühl S, Hersberger K. Change of body weight and lifestyle after counselling of persons at risk for type 2 diabetes: follow-up study of a screening campaign in Swiss community pharmacies. *Pharm World Sci* 2006;in press.
8. Christians U, Schmitz V, Haschke M. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. *Expert Opin. Drug Metab. Toxicol.* (2005) 1(4): 641-54
9. Christians U, Strom T, Zhang YL, Steudel W, Schmitz V, Trump S, Haschke M: Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. *Ther Drug Monit.* 2006 Feb;28(1):39-44

10. Degen L, Matzinger D, Drewe J, Nissle S, Maecke H, Lengsfeld h, Hadvary P, Beglinger C: Role of fatty acids in regulating gastric emptying and gallbladder contraction. *Digestion* 399: xxx (2006)
11. Drewe J. Interaktionen zwischen Antiepileptika und Antidepressiva / Neuroleptika. *Epileptologie* 23 (1): 23-26 (2006)
12. Egger SS, Gehrig Studer I, Rätz Bravo AE, Krähenbühl S. Minocyclin-induzierter Lupus erythematodes. *Schweiz Rundsch Med Prax* 2006;95:1155-61.
13. Egger SS, Bachmann A, Hubmann N, Schlienger R, Krähenbühl S. Prevalence of potentially inappropriate medications in elderly patients: comparison between internal medical and geriatric wards. *Drugs Aging* 2006;23:823-37.
14. Grunder G, Zysset-Aschmann Y, Vollenweider F, Maier T, Krähenbühl S, Drewe J. Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers. *Antimicrobial Agents Chemother* 2006; 50(1):68-72
15. Gutmann H, Poller B, Berger B, Pfrunder A, Schaffner W and Drewe J. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? *Planta Medica* 72(8): 685-90 (2006)
16. Gutzwiller JP, Hruz P, Huber AR, Hamel C, Zehnder C, Drewe J, Gutmann H, Vogel D, Beglinger C: Glucagon-Like Peptide-1 Is Involved in Sodium and Water Homeostasis in Humans. *Digestion* 73:142–150 (2006)
17. Haschke M. Interaktionen zwischen Antiepileptika und oralen Antidiabetika. *Epileptologie* 23 (1): 2-7 (2006)
18. Huwyler J, Wright MB, Gutmann H and Drewe J: Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin *Current Drug Metab* 2006 Feb;7(2):119-26.(2006)
19. Hruz P, Zimmermann C, Gutmann H, Degen L, Beuers U, Terracciano L, Drewe J, and Beglinger C: Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. *Gut* 55: 395-402 (2006)

20. Indermitte J, Burkolter S, Drewe J, Krähenbühl S, Hersberger KE: Risk factors associated with a high velocity to develop hyperkalaemia in hospitalised patients. *Drug Safety* (2006) - in press
21. Kaufmann P, Haschke M, Török M, Beltinger J, Bogman K, Wenk M, Terracciano L, Krähenbühl S. Mechanisms of venoocclusive disease for the combination of cyclophosphamide and roxithromycin. *Ther Drug Monit* 2006;in press.
22. Kaufmann P, Török M, Zahno A, Waldhauser KM, Brecht K, Krähenbühl S. Toxicity of statins on rat skeletal muscle mitochondria. *Cell Mol Life Sci* 2006;63:2415-25
23. Krähenbühl S. Mit Mangelernährung assoziierte Medikamente: ein Problem im Alter? *Schweizer Zeitschrift für Ernährungsmedizin* 2006;5:22-27
24. Maier M, Zimmermann C, Beglinger C, Drewe J, Gutmann H. Effects of budesonide on P-glycoprotein expression in intestinal cell lines. *Br J Pharmacol* (2006) - in press
25. Marston A, Leibundgut G, Kühne M, Rätz Bravo A, Hofer S, Ludwig C. Eine tödliche Arzneimittelinteraktion. *Schweiz Med Forum* 2006;6:350–352
26. Lampert ML, Krähenbühl S, Hersberger K, Schlienger RG. Clinical pharmacy and pharmaceutical care: patient-oriented application of pharmaceutical expertise. *Chimia* 2006;60:58-61
27. Netsch MI, Gutmann H, Schmidlin CB, Aydogan C, Drewe J. Induction of CYP1A by green tea extract in human intestinal cell line. *PLanta Medica* 72(6):514-20 (2006)
28. Netsch MI, Gutmann H, Aydogan C, Drewe J. Green tea extract induces interleukin-8 (IL-8) mRNA and protein expression but specifically inhibits IL-8 secretion in Caco-2 cells. *PLanta Medica* 72(8):697-702 (2006)
29. Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, Hess L, Schlienger RG, Krähenbühl S. Prävalenz potentieller Arzneimittel-Interaktionen bei ambulanten Patienten unter Statin-Therapie. *Praxis* 2006;95:139-46.

30. Ramelli GP, Gallati S, Weis J, Krähenbühl S, Burgunder J-M. Point mutation tRNA Ser(UCN) in a child with hearing loss and myoclonus epilepsy. *J Child Neurology* 2006; 21:253-5.
31. Philippsen C, Hahn M, Schwabe L, Richter S, Drewe J, Schächinger H. Cardiovascular reactivity to mental stress is not affected by alpha2-adrenoreceptor activation or inhibition. *Psychopharmacology* (2006) - in press
32. Schlatter P, Gutmann H, Drewe J. Primary porcine proximal tubular cells as a model for transepithelial drug transport in human kidney. *Eur J Pharm Sci.* 28(1-2):141-54 (2006)
33. Schächinger H, Klarhöfer M, Linder L, Drewe J, Scheffler K. Angiotensin II decreases the renal MRI BOLD signal. *Hypertension* (2006) - in press
34. Schmitz V, Klawitter J, Bendrick-Peart J, Haschke M, Beckey VE, Laudi S, Neumann U, Schoening W, Neuhaus P, Christians U, Puhl G: Impact of Organ Preservation Using HTK for Graft Flush and Subsequent Storage in UW in Rat Kidney Transplantation, *Eur Surg Res* 2006;38:388–398
35. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, Krähenbühl S, Chadha-Boreham H, Dingemans J. Pharmacodynamics and pharmacokinetics of the urotensin-II receptor antagonist palosuran in macroalbuminuric, diabetic patients. *Clin Pharmacol Ther*, 80:246-56 (2006).
36. Stettler C, Allemann S, Jueni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P. Glycemic control and macrovascular disease in type 1 and 2 diabetes mellitus: meta-analysis of randomized trials. *Am Heart J* 152(1): 27-38 (2006).
37. Straubhaar B, Krähenbühl S, Schlienger RG. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. *Drug Saf.* 2006;29(1):79-90.
38. Tschambaz L, Schlatter C, Jakob M, Krähenbühl A, Wolf P, Krähenbühl S. Dose adaptation of antineoplastic drugs in patients with liver disease. *Drug Safety* ; 29: 509-522 (2006).
39. Todesco L, Waldhauser K, Krähenbühl S. Mitochondrial toxicity of drugs. *Chimia* 2006;60:37-39

40. Vernez L, Dickenmann M, Steiger J, Wenk M, Krähenbühl S. Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis. *Nephrol Dial Transplant* 2006 21(2):450-8. Epub 2005 Nov 11.
41. Waldhauser KM, Török M, Ha H-R, Thomet U, Konrad D, Brecht K, Follath F, Krähenbühl S. Hepatocellular toxicity and pharmacological effects of amiodarone and amiodarone derivatives. *J Pharmacol Exp Ther* 2006;in press.
42. Wenk M, Droll A, Krähenbühl S. Determination of the antifungal drug voriconazole in plasma using monolithic silica rod liquid chromatography. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2006;832:313-6
43. Wenk M, Haegeli L, Brunner HP, Krähenbühl S. Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. *J Pharm Biomed Anal* 41: 1367-70 (2006).
44. Zhang YL, Bendrick-Peart J, Strom T, Haschke M, Christians U. Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples. *Ther Drug Monit.* 2005 Dec;27(6):770-8.
45. Zimmermann C, Gutmann H, Drewe J. Thalidomide does not interact with P-glycoprotein. *Cancer Chemother Pharmacol* 57(5): 599-606 (2006)
46. Zimmermann C, Gloede H. Interaktionen zwischen Antiepileptika und antiinfektiver / antiretroviraler Medikation. *Epileptologie* 23 (1): 27-31 (2006)
47. Zimmermann C, Hruz P, Gutmann H, Terracciano L, Beuers U, Lehmann F, Beglinger C, Drewe J: Decreased expression of breast cancer resistance protein (BCRP) in the duodenum in patients with obstructive cholestasis. *Digestion* (2006)
48. Zysset-Aschmann Y. Interaktionen zwischen Antiepileptika und Zytostatika. *Epileptologie* 23 (1): 32--37 (2006)